Trading Analysis Report: BUD
- Analysis date: 2026-05-29
- Processed decision: Buy
- Price Target: $93
I. Analyst Team Reports
Market Analyst
Market Analyst
Investment Snapshot
| Metric | Latest value | Why it matters |
|---|---|---|
| NYSE close (May 29, 2026) | $79.99 | Entry price for the rating and target. |
| Market capitalization | $154.85B | BUD is a global mega-cap brewer with defensive consumer staples exposure. |
| Enterprise value | $227.88B | Debt makes enterprise value the more relevant valuation frame. |
| 52-week range | $56.97-$84.46 | Shares are close to the upper end of the one-year range. |
| 50-day / 200-day averages | $75.60 / $67.98 | Price remains above both trend lines, showing positive momentum. |
| Forward P/E | 16.25x | Valuation is reasonable for a global branded staples compounder. |
| Trailing P/E | 22.16x | Current earnings multiple is not cheap but still below many premium staples peers. |
| Price/sales | 2.54x | Revenue multiple is moderate for a high-margin brand portfolio. |
| EV/EBITDA | 11.56x | Enterprise multiple is fair given leverage and improving EBITDA. |
| Dividend yield | 1.68% | Income is secondary to earnings growth and buybacks. |
| Analyst mean / median target | $92.73 / $92.92 | Consensus implies mid-teens upside from the close. |
| Analyst high / low target | $105.00 / $83.00 | Even the low target sits above the current close. |
| Q1 2026 revenue | $15.267B, +5.8% organic | Organic growth came from volume, price/mix, and premiumization. |
| Q1 2026 beer volume | +1.2% | Beer volume returned to growth, supporting the category recovery thesis. |
| Q1 2026 normalized EBITDA | $5.437B, +5.3% | EBITDA grew despite higher marketing investment and FX headwinds. |
| Q1 2026 EBITDA margin | 35.6% | Margin was broadly stable, down 15 bps. |
| Q1 2026 underlying EPS | $0.97, +20.8% | EPS growth was the strongest headline and reached a Q1 record. |
| FY2026 EBITDA outlook | +4% to +8% | Management reaffirmed medium-term growth delivery. |
| FY2025 revenue / EBITDA | $59.3B / $21.2B | Establishes the annual scale and profit base. |
| Buyback progress | $1.4B of $6.0B completed | Capital return adds support if cash generation persists. |
| Total debt / cash | $73.33B / $11.94B | Leverage remains the main balance-sheet risk. |
BUD closed at $79.99 on May 29, 2026, with a market capitalization of about $154.85 billion and an enterprise value of about $227.88 billion. The share price is near the upper end of its 52-week range and above both the 50-day and 200-day averages, so momentum is positive but not at a distressed entry point.
Valuation is acceptable rather than cheap. The stock trades at 16.25x forward earnings, 22.16x trailing earnings, 2.54x sales, and 11.56x EV/EBITDA. Given the company's scale, brand portfolio, and improving operating trend, those multiples can support a constructive rating if Q1 momentum continues.
The market setup supports a Buy rating with a $93 target. That target is close to the analyst mean of $92.73 and median of $92.92, and it implies mid-teens price upside from $79.99 before dividends. The main reason not to be more aggressive is that the stock is already close to its 52-week high and still carries a large debt load.
Sentiment Analyst
Sentiment Analyst
Sentiment toward BUD improved after first-quarter 2026 results. AB InBev reported organic revenue growth of 5.8%, total volume growth of 0.8%, beer volume growth of 1.2%, and a 20.8% increase in underlying EPS to $0.97. The result directly addresses the market's concern that the company was mainly relying on price and mix rather than returning to volume growth.
The brand story is also supportive. Megabrand revenue rose 8.2%, with Corona up 16%, Stella Artois up 14%, and Michelob Ultra up 39% outside their home markets. No-alcohol beer revenue grew 27%, Beyond Beer grew 37%, and BEES Marketplace GMV rose 55% to $1.1 billion.
Sentiment is not risk-free. The U.S. remains a watch item despite sales-to-retailers growth of 0.3%, because sales-to-wholesalers declined 3.2%. China also remains weak, with revenue down 3.9% and EBITDA down 11.8%. The sentiment case is positive, but it depends on continued U.S. stabilization and emerging-market strength.
News Analyst
News Analyst
The key news item is AB InBev's first-quarter 2026 results release dated May 5, 2026. Reported revenue increased 12.0% to $15.267 billion, while organic revenue increased 5.8%. Total volumes rose 0.8%, beer volumes rose 1.2%, and revenue per hectoliter increased 4.5%.
Profitability was solid. Normalized EBITDA rose 5.3% to $5.437 billion, with a 35.6% margin. Profit attributable to equity holders was $2.563 billion, underlying profit was $1.923 billion, basic EPS was $1.30, and underlying EPS rose 20.8% to $0.97.
Management also reiterated the FY2026 outlook. AB InBev expects EBITDA to grow 4%-8%, normalized effective tax rate of 26%-28%, and net capital expenditure of $3.5 billion to $4.0 billion. The company also disclosed that it had completed about $1.4 billion of its $6.0 billion buyback program as of May 1, 2026. FY2025 context from the investor page shows 561.1 million hL of volume, $59.3 billion of net revenue, $21.2 billion of normalized EBITDA, and $3.73 of underlying EPS.
Sources: AB InBev first-quarter 2026 results release dated May 5, 2026; AB InBev full-year and fourth-quarter 2025 results release; AB InBev investor page; market snapshot retrieved May 31, 2026 for the May 29, 2026 NYSE close.
Fundamentals Analyst
Fundamentals Analyst
AB InBev's fundamentals are improving. Q1 2026 organic revenue grew 5.8%, normalized EBITDA grew 5.3%, and underlying EPS grew 20.8%. The key positive is that beer volume growth returned to positive territory at 1.2%, while revenue per hectoliter still increased 4.5%. That combination supports both volume recovery and price/mix durability.
The company has meaningful annual scale. FY2025 performance showed 561.1 million hL of total volume, $59.3 billion of net revenue, $21.2 billion of normalized EBITDA, and $3.73 of underlying EPS. Q1 2026 suggests the company can compound from that base if premium brands, no-alcohol beer, Beyond Beer, and BEES continue scaling.
The balance sheet is the main constraint. Market data shows about $73.33 billion of total debt and $11.94 billion of cash. This makes EV/EBITDA more important than equity P/E, and it is the reason the target should stay near consensus rather than stretch toward the high target. Still, buyback execution and EBITDA growth can gradually improve equity value if leverage remains controlled.
II. Research Team Decision
Bull Researcher
Bull Case
The bull case is that AB InBev is returning to balanced growth: volume, price/mix, margin discipline, and capital returns are all contributing. Q1 beer volume rose 1.2%, organic revenue grew 5.8%, normalized EBITDA grew 5.3%, and underlying EPS rose 20.8%. Those figures support the view that the company is not just cutting costs or taking price; it is rebuilding category momentum.
Brand and platform assets strengthen the case. Corona, Stella Artois, and Michelob Ultra delivered strong growth outside home markets, no-alcohol beer and Beyond Beer are scaling quickly, and BEES Marketplace GMV reached $1.1 billion. If management delivers 4%-8% EBITDA growth and continues the $6 billion buyback, the stock can move toward the $93 base target and potentially higher.
Bear Researcher
Bear Case
The bear case is that BUD is no longer cheap after its rerating. The stock is near its 52-week high and trades at 11.56x EV/EBITDA with a large debt balance. If revenue growth slows, the multiple could compress quickly.
Regional risks remain visible. U.S. sales-to-wholesalers declined 3.2% in Q1, and China revenue declined 3.9% with EBITDA down 11.8%. The company also needs continued marketing investment around global events, which can limit margin expansion. If volume growth fades or debt reduction stalls, upside toward the analyst target could narrow.
Research Manager
Research Manager Decision
The balanced decision is Buy. AB InBev's first-quarter 2026 results show a cleaner growth mix than in prior periods: organic revenue increased 5.8%, beer volumes grew 1.2%, normalized EBITDA increased 5.3%, and underlying EPS rose 20.8%. Management also reaffirmed the 4%-8% FY2026 EBITDA growth outlook.
Price Target: $93
The $93 target is aligned with the analyst mean and median targets and implies mid-teens upside from $79.99. The rating is not a high-conviction aggressive Buy because the stock is near its 52-week high and leverage remains significant, but the combination of volume recovery, premium brand growth, buybacks, and fair valuation supports a positive stance.
III. Trading Team Plan
Trader
Trading Plan
Rating: Buy
Price Target: $93
Time Horizon: 6-12 months
Investment Snapshot
| Metric | Latest value | Why it matters |
|---|---|---|
| NYSE close (May 29, 2026) | $79.99 | Entry price for the rating and target. |
| Market capitalization | $154.85B | BUD is a global mega-cap brewer with defensive consumer staples exposure. |
| Enterprise value | $227.88B | Debt makes enterprise value the more relevant valuation frame. |
| 52-week range | $56.97-$84.46 | Shares are close to the upper end of the one-year range. |
| 50-day / 200-day averages | $75.60 / $67.98 | Price remains above both trend lines, showing positive momentum. |
| Forward P/E | 16.25x | Valuation is reasonable for a global branded staples compounder. |
| Trailing P/E | 22.16x | Current earnings multiple is not cheap but still below many premium staples peers. |
| Price/sales | 2.54x | Revenue multiple is moderate for a high-margin brand portfolio. |
| EV/EBITDA | 11.56x | Enterprise multiple is fair given leverage and improving EBITDA. |
| Dividend yield | 1.68% | Income is secondary to earnings growth and buybacks. |
| Analyst mean / median target | $92.73 / $92.92 | Consensus implies mid-teens upside from the close. |
| Analyst high / low target | $105.00 / $83.00 | Even the low target sits above the current close. |
| Q1 2026 revenue | $15.267B, +5.8% organic | Organic growth came from volume, price/mix, and premiumization. |
| Q1 2026 beer volume | +1.2% | Beer volume returned to growth, supporting the category recovery thesis. |
| Q1 2026 normalized EBITDA | $5.437B, +5.3% | EBITDA grew despite higher marketing investment and FX headwinds. |
| Q1 2026 EBITDA margin | 35.6% | Margin was broadly stable, down 15 bps. |
| Q1 2026 underlying EPS | $0.97, +20.8% | EPS growth was the strongest headline and reached a Q1 record. |
| FY2026 EBITDA outlook | +4% to +8% | Management reaffirmed medium-term growth delivery. |
| FY2025 revenue / EBITDA | $59.3B / $21.2B | Establishes the annual scale and profit base. |
| Buyback progress | $1.4B of $6.0B completed | Capital return adds support if cash generation persists. |
| Total debt / cash | $73.33B / $11.94B | Leverage remains the main balance-sheet risk. |
New capital can be accumulated selectively below $80, with a preference for staged entries because the stock is near its 52-week high. The initial risk/reward is favorable against a $93 target, but the position should not be oversized unless the company confirms that Q1 volume recovery continues into the next quarter.
A move above the $84.46 52-week high would be constructive if supported by sustained beer volume growth, stable U.S. demand, and continued EBITDA growth within the 4%-8% outlook. Risk controls should tighten if the stock loses the 50-day average or if management signals renewed weakness in the U.S. or China.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
An aggressive investor can own BUD for earnings recovery and global brand momentum. The company delivered 20.8% underlying EPS growth in Q1, volume growth returned, and the buyback is meaningful. If management executes the FY2026 EBITDA outlook and the market prices BUD more like a premium staples compounder, the stock can trade above the $93 base target.
The aggressive case should still respect leverage. Total debt remains high, and EV/EBITDA is the better risk metric than P/E. Position sizing should account for consumer demand and currency volatility.
Conservative Analyst
Conservative Risk View
A conservative investor can hold or add modestly, but should avoid chasing a full position after the recent rerating. BUD is near its 52-week high, the dividend yield is only 1.68%, and leverage remains significant. The company is improving, but the risk profile is not as defensive as a low-debt staples company.
For conservative portfolios, the best setup is staged buying on pullbacks toward the 50-day average or after another quarter confirms that beer volumes and EBITDA are still growing. Existing holders can continue to hold while monitoring net debt, U.S. wholesaler shipments, China performance, and buyback execution.
Neutral Analyst
Neutral Risk View
The neutral view supports Buy with a $93 target, but not a stretched target. Q1 2026 showed broad improvement, and consensus targets are above the current price. At the same time, the stock is close to its one-year high, and the company still needs to prove that U.S. stabilization and China recovery can last.
Key monitoring points are beer volume growth, revenue per hectoliter, normalized EBITDA margin, U.S. STR/STW convergence, China revenue trends, net debt, and progress on the $6 billion buyback.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Final Rating: Buy
Price Target: $93
Investment Snapshot
| Metric | Latest value | Why it matters |
|---|---|---|
| NYSE close (May 29, 2026) | $79.99 | Entry price for the rating and target. |
| Market capitalization | $154.85B | BUD is a global mega-cap brewer with defensive consumer staples exposure. |
| Enterprise value | $227.88B | Debt makes enterprise value the more relevant valuation frame. |
| 52-week range | $56.97-$84.46 | Shares are close to the upper end of the one-year range. |
| 50-day / 200-day averages | $75.60 / $67.98 | Price remains above both trend lines, showing positive momentum. |
| Forward P/E | 16.25x | Valuation is reasonable for a global branded staples compounder. |
| Trailing P/E | 22.16x | Current earnings multiple is not cheap but still below many premium staples peers. |
| Price/sales | 2.54x | Revenue multiple is moderate for a high-margin brand portfolio. |
| EV/EBITDA | 11.56x | Enterprise multiple is fair given leverage and improving EBITDA. |
| Dividend yield | 1.68% | Income is secondary to earnings growth and buybacks. |
| Analyst mean / median target | $92.73 / $92.92 | Consensus implies mid-teens upside from the close. |
| Analyst high / low target | $105.00 / $83.00 | Even the low target sits above the current close. |
| Q1 2026 revenue | $15.267B, +5.8% organic | Organic growth came from volume, price/mix, and premiumization. |
| Q1 2026 beer volume | +1.2% | Beer volume returned to growth, supporting the category recovery thesis. |
| Q1 2026 normalized EBITDA | $5.437B, +5.3% | EBITDA grew despite higher marketing investment and FX headwinds. |
| Q1 2026 EBITDA margin | 35.6% | Margin was broadly stable, down 15 bps. |
| Q1 2026 underlying EPS | $0.97, +20.8% | EPS growth was the strongest headline and reached a Q1 record. |
| FY2026 EBITDA outlook | +4% to +8% | Management reaffirmed medium-term growth delivery. |
| FY2025 revenue / EBITDA | $59.3B / $21.2B | Establishes the annual scale and profit base. |
| Buyback progress | $1.4B of $6.0B completed | Capital return adds support if cash generation persists. |
| Total debt / cash | $73.33B / $11.94B | Leverage remains the main balance-sheet risk. |
Anheuser-Busch InBev should be rated Buy with a $93 target. Q1 2026 delivered a stronger mix of growth than the market has seen recently: reported revenue of $15.267 billion, organic revenue growth of 5.8%, beer volume growth of 1.2%, normalized EBITDA of $5.437 billion, and underlying EPS growth of 20.8% to $0.97. Management also reaffirmed its FY2026 EBITDA growth outlook of 4%-8%.
The investment case is a disciplined recovery and capital-return story. AB InBev has global scale, premium megabrands, growth in no-alcohol and Beyond Beer, and a meaningful buyback program. At 16.25x forward earnings and 11.56x EV/EBITDA, valuation is fair for a company returning to volume growth.
The main risks are leverage, U.S. shipment volatility, China weakness, and the possibility that the stock's move near its 52-week high has pulled forward some upside. The portfolio stance should be constructive but staged: buy selectively around current levels, prefer pullbacks for larger adds, and reassess if volume growth or EBITDA guidance weakens.